



# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Nulibry Clinical Edit
<b>First Implementation Date:</b>	November 18, 2021
<b>Revised Date:</b>	TBD
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input checked="" type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of Nulibry™ (fosdenopterin)

**Why Issue Selected:** On February 26, 2021, Nulibry™ became the first FDA-approved agent to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, a rare condition with a median age of survival of 4 years that is estimated to occur in 1 in 100,000 - 200,000 newborns worldwide. Three types of MoCD have been classified: Type A, Type B, and Type C. Type A, the most common type, is an autosomal recessive condition caused by a mutation in the molybdenum cofactor synthesis 1 (MOCS1) gene which leads to deficient synthesis of cyclic pyranopterin monophosphate (cPMP). The resultant downstream effect of the DNA sequence change includes a buildup of the neurotoxic metabolite S-sulfocysteine (SSC), which leads to rapid and irreversible neurological damage. Patients with the classical severe form of MoCD often develop the characteristic signs/symptoms of encephalopathy, intractable seizures, feeding difficulties, and developmental delays within the first few days of life.

Prior to Nulibry, no therapeutic alternatives existed beyond supportive therapies, such as those for the management of seizures. Nulibry, administered as a once daily intravenous infusion, functions as a substrate replacement therapy by providing an exogenous source of cPMP. Clinical trials demonstrated an increased 3-year survival rate of 84% vs 55% in patients treated with Nulibry compared to those from a natural history study. The most common side effects were catheter-related complications, pyrexia, and viral infections. Due to the high cost and specific approved indication, MO HealthNet will impose clinical criteria to ensure appropriate utilization of Nulibry.

Program-Specific Information:	Drug	Cost per vial	Cost per year (maintenance dosing based on a 20 kg patient)
	NULIBRY 9.5 MG VIAL	\$1,369.86 WAC	\$986,300 WAC

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Nulibry™ (fosdenopterin)
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

### Initial Therapy:

- Confirmed or suspected molybdenum cofactor deficiency (MoCD) Type A **AND**
- Prescribed by or in consultation with a neonatologist or other specialist in the treated disease state

### Continuation of Therapy:

- Initial approval is for 3 months, renewal of prior authorization may be given following documentation of the following:
  - Genetic testing to confirm biallelic pathogenic variant of *MOCS1* gene **AND**
  - Claim does not exceed 0.9 mg/kg per day

## Denial Criteria

- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:

X

Progress Notes:

X

MedWatch Form:

Other:

## Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)

Rule Type: CE

## Default Approval Period

1 year

## References

- NULIBRY™ (fosdenopterin) [package insert]. Boston, MA: Origin Biosciences, Inc. February 2021.
- Nagappa, M., Bindu, P.S., Taly, A.B. Child Neurology: Molybdenum cofactor deficiency. *American Journal of Neurology*. December 8, 2015; 85(23). <https://n.neurology.org/content/85/23/e175>. Accessed 12 March 2021.
- IPD Analytics. New Drug Review: Nulibry (fosdenopterin). March 2021.
- BridgeBio Pharma's Origin Biosciences Presents New Data On The Natural History Of Molybdenum Cofactor Deficiency (MoCD) Type A At The Society Of The Study Of Inborn Errors Of Metabolism (SSIEM) Conference. September 5, 2019. <https://bridgebio.com/news/bridgebio-pharmas-origin-biosciences-presents-new-data-on-the-natural-history-of-molybdenum-cofactor-deficiency-mocd-type-a-at-the-society-of-the-study-of-inborn-errors-of-metabolism-ssiem>. Accessed 12 March 2021.
- Scelsa, B., Gasperini, S., Righini A., et. Al. Mild phenotype in Molybdenum cofactor deficiency: A new patient and review of the literature. *Molecular Genetics & Genomic Medicine*. 2019 June; 7(6): e657. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565584/>. Accessed 17 March 2021.

### SmartPA Clinical Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.